Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The protein encoded by PPP1R14A belongs to the protein phosphatase 1 (PP1) inhibitor family. Additionally we are shipping Protein Phosphatase 1, Regulatory (Inhibitor) Subunit 14A Proteins (15) and Protein Phosphatase 1, Regulatory (Inhibitor) Subunit 14A Kits (1) and many more products for this protein.
Showing 10 out of 43 products:
Human Monoclonal PPP1R14A Primary Antibody for EIA, WB - ABIN302213
Hamaguchi, Ito, Feng, Seko, Koyama, Machida, Takase, Amano, Kaibuchi, Hartshorne, Nakano: Phosphorylation of CPI-17, an inhibitor of myosin phosphatase, by protein kinase N. in Biochemical and biophysical research communications 2000
Show all 3 references for ABIN302213
Human Polyclonal PPP1R14A Primary Antibody for IF - ABIN401630
Hagerty, Weitzel, Chambers, Fortner, Brush, Loiselle, Hosoya, Haystead: ROCK1 phosphorylates and activates zipper-interacting protein kinase. in The Journal of biological chemistry 2007
Hoxb1b is likely to directly regulate ppp1r14al expression in rhombomere 4. Furthermore, ppp1r14al is essential for establishment of the earliest hindbrain signaling-center in rhombomere 4 by regulating expression of fgf3 (show FGF3 Antibodies).
CPI-17 has a role in restoring skin homoeostasis in cutaneous field of cancerization lesions
analysis of the interaction between plakoglobin (show JUP Antibodies) and CPI-17, which is affected by the phosphorylation status of CPI-17 in human lung microvascular endothelial cells
The N-terminal 21-residue tail domain of CPI-17 is necessary for nuclear localization. Phospho-mimetic Asp (show ASIP Antibodies)-substitution of CPI-17 at Ser12 attenuates the nuclear import.
The study characterized the CPI-17 promoter and identified binding sites for GATA-6 (show GATA6 Antibodies) and nuclear factor kappa B (NF-kappaB (show NFKB1 Antibodies)).
a novel signaling cascade that links RhoA (show RHOA Antibodies)-mediated calcium sensitivity to MEF2 (show MEF2A Antibodies)-dependent myocardin (show MYOCD Antibodies) expression in VSMCs through a mechanism involving p38 MAPK (show MAPK14 Antibodies), PP1alpha (show PPP1CA Antibodies), and CPI-17.
RACK1 (show GNB2L1 Antibodies) may play a role in PKC (show PRRT2 Antibodies)/CPI-17 signaling pathway.
cAMP/PKA regulates the endothelial barrier via inhibition of the contractile machinery, mainly by the activation of MLCP via inhibition of CPI-17 and RhoA (show RHOA Antibodies)/Rock.
mapped to chromosome 19q13.13-q13.2
CPI-17 binds directly to protein kinase C (show PKC Antibodies) and casein kinase I (show CSNK1D Antibodies).
importance of PKC (show PRRT2 Antibodies)/CPI-17-mediated pathway in histamine-triggered cytoskeletal rearrangements leading to lung microvascular barrier compromise.
Enhanced vasorelaxation in early endotoxemia is mediated by redox signaling through PKG-1alpha but in later endotoxemia by myosin phosphatase isoform shifts enhancing sensitivity to NO/cGMP as well as smooth muscle atrophy.
a novel signaling cascade that links RhoA (show RHOA Antibodies)-mediated calcium sensitivity to MEF2 (show MEF2C Antibodies)-dependent myocardin (show MYOCD Antibodies) expression in VSMCs through a mechanism involving p38 MAPK (show MAPK14 Antibodies), PP1alpha (show PPP1CA Antibodies), and CPI-17.
Data suggest that CPI-17 and both conventional and novel PKC isozymes contribute to the phasic and tonic contractile components of BALB/c colonic circular smooth muscle.
Organ-specific mechanisms involving MYPT1 (show PPP1R12A Antibodies), M-RIP (show MPRIP Antibodies), and CPI-17 are critical to regulating basal LC20 (show MYL9 Antibodies) phosphorylation in gastrointestinal smooth muscles.
calcium-independent phospholipase A2beta has a role in high glucose-induced activation of RhoA (show RHOA Antibodies), Rho kinase (show ROCK2 Antibodies), and CPI-17 in cultured vascular smooth muscle cells and vascular smooth muscle hypercontractility in diabetic animals
distribution of mouse and rat PPP1R14A was more specific and different from that of humans
concluded that actions downstream of cGMP/PKG (show PRKG1 Antibodies) can reverse PKC (show PKC Antibodies)-mediated phosphorylation of CPI-17 and Ca(2 (show CA2 Antibodies)+) sensitization in smooth muscle
findings suggest that CPI-17 was downregulated during intestinal inflammation and that TNF-alpha (show TNF Antibodies) plays a central role in this process. Downregulation of CPI-17 may play a role in motility impairments in inflammation.
CPI-17 expression is reversibly controlled in response to the phenotype transition of smooth muscle cells that restricts the signal to differentiated smooth muscle cells and particular cell types.
This study examined the protein expression and spatial-temporal distribution of PKCalpha (show PKCa Antibodies) and CPI-17 in intact smooth muscle tissues.
The protein encoded by this gene belongs to the protein phosphatase 1 (PP1) inhibitor family. This protein is an inhibitor of smooth muscle myosin phosphatase, and has higher inhibitory activity when phosphorylated. Inhibition of myosin phosphatase leads to increased myosin phosphorylation and enhanced smooth muscle contraction. Alternatively spliced transcript variants encoding different isoforms have been noted for this gene.
protein phosphatase 1, regulatory (inhibitor) subunit 14A
, protein phosphatase 1 regulatory subunit 14A
, 17 kDa PKC-potentiated inhibitory protein of PP1
, 17-KDa protein
, 17-kDa PKC-potentiated inhibitory protein of PP1
, PKC-potentiated inhibitory protein of PP1
, protein kinase C-potentiated inhibitor protein of 17 kDa